Cytomegalovirus

Moderna announced positive interim results from a phase 3 trial of its next-generation COVID-19 vaccine, which the company said will help pave the way for its combination shot against COVID-19 and influenza.

Among transplant recipients treated for cytomegalovirus, resistance to maribavir was less common than resistance to investigator-assigned standard therapy, at baseline and post-treatment, researchers reported.

The FDA recently approved a new indication for Prevymis as a prophylaxis to prevent cytomegalovirus disease in high-risk adult kidney transplant patients receiving organs from CMV-seropositive donors.

Merck announced the FDA accepted two supplemental new drug applications for Prevymis, also known as letermovir, and granted the application priority review, according to the press release.

Takeda Pharmaceuticals Company Limited announced FDA approval of Livtencity as the first treatment for patients 12 years or older who weigh at least 35 kg and have cytomegalovirus infection after transplant that is refractory to treatment.

U.S. data revealed that cytomegalovirus was independently associated with latent tuberculosis infection, and both were associated with high levels of C-reactive protein, suggesting enhanced systemic inflammation, researchers reported.

The FDA granted priority review to maribavir for the treatment of patients with transplant-associated cytomegalovirus infection that was resistant or refractory to prior treatment, according to the agent’s manufacturer.

Although potentially curative for many hematologic malignancies, hematopoietic stem cell transplantation historically has been associated with substantial morbidity and mortality.

Letermovir reduced clinically significant cytomegalovirus reactivation among patients who underwent allogeneic hematopoietic stem cell transplant, according to retrospective results presented at TCT Meetings Digital Experience.

Early cytomegalovirus reactivation after allogeneic stem cell transplantation induced cytomegalovirus antigen-specific T cells that may better prevent future infection, according to results of a retrospective study.